HeliosX, the London-based online pharmacy, has made significant strides in the weight-loss drug market, recently boasting a remarkable reduction of 8.5 million kilograms in patient weight, equating to approximately 3.5
Pharmaceutical2- Page
192Articles
Recent developments regarding Iran’s threats to close the Strait of Hormuz have sparked significant concerns among pharmacists and healthcare professionals in the UK. As a crucial maritime route for oil
Novo Nordisk, Denmark’s leading pharmaceutical company known for its weight management medications, has encountered significant economic hurdles recently. After achieving initial success with its medications Wegovy and Ozempic, the company
Hikma Pharmaceuticals, a leading FTSE 100 company in the pharmaceuticals sector, has seen a significant decline in its share price following the announcement of weaker financial forecasts and the scrapping
GSK has announced a significant acquisition, reaching a deal worth $950 million to purchase 35Pharma, a Canadian biopharmaceutical company with a focus on developing therapies for lung diseases linked to
A head-to-head trial of Novo Nordisk’s next-generation obesity drug, CagriSema, has revealed disappointing results in comparison to rival Eli Lilly’s Mounjaro. The trial results have triggered a significant sell-off in
Santhera Pharmaceuticals has released eight year clinical data for its Duchenne muscular dystrophy treatment Agamree that could fundamentally alter therapeutic approaches to this devastating condition, yet market recognition of this
Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF, FRA:WQ5) has clarified the rationale behind its recent announcement regarding share issuance authority ahead of its annual general meeting, emphasising that the move is designed
A subsidiary of AstraZeneca in China, along with a former leading executive and a senior employee, has been indicted on various charges by the prosecutor in Shenzhen. The investigation has
Citi has increased its price target for GSK PLC (LSE:GSK, NYSE:GSK) to £22.50 whilst maintaining a neutral rating on the pharmaceutical group following a notable rally in the shares driven
The Danish pharmaceutical company Novo Nordisk has seen its shares decline by nearly 50 per cent over the past year, following a warning of a significant drop in profits and
GSK is evaluating potential cost-saving measures and manufacturing adjustments in Europe as it aims to invest in the launch of new products while moving away from older legacy drugs. City
Speculation surrounding a potential merger between GlaxoSmithKline and AstraZeneca has gained traction as GSK’s leadership undergoes a transition. Analysts recently suggested that the appointment of Luke Miels as GSK’s new
Orca Bio has secured 250 million USD in funding across two financing rounds, significantly strengthening its balance sheet as the company prepares for the potential commercialisation of its blood cancer
GSK has announced headline data from two pivotal phase III trials for bepirovirsen, a chronic hepatitis B treatment that could transform care for a disease affecting approximately 250 million people
Novo Nordisk has introduced the first oral formulation of its blockbuster GLP-1 weight loss medication to the United States market, marking a significant shift in the pharmaceutical landscape for obesity
